Whitehawk Therapeutics
WHWK
46 hedge funds and large institutions have $294M invested in Whitehawk Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
39% more funds holding
Funds holding: 33 → 46 (+13)
5.08% more ownership
Funds ownership: 53.3% → 58.37% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less capital invested
Capital invested by funds: $324M → $294M (-$29.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.82M |
| 3 |
BlackRock
New York
|
+$7.37M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$5.02M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$10.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$6.22M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.67M |
| 4 |
O
OrbiMed
New York
|
-$5.49M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.11M |
WHWK Hedge Fund Activity: Q4 2021 in Review
46 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2021, worth a combined $294M — down 9.2% from $324M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new WHWK positions and 6 closed out — a net gain of 13 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $16.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $10.2M sold.
- 46 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2021, up from 33 in Q3 2021.
- Funds reported $294M of Whitehawk Therapeutics stock for Q4 2021, down 9.2% quarter-over-quarter.
- 19 funds opened new Whitehawk Therapeutics positions in Q4 2021 and 6 closed out, a net change of +13 holders.
- The largest Whitehawk Therapeutics buyer in Q4 2021 was Vanguard Group, an estimated $16.2M added.
- The largest Whitehawk Therapeutics seller in Q4 2021 was RA Capital Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2021.